BIOA BioAge Labs Inc.
QT11Latest market price
5.96
+0.16+2.76%
Earnings
Up 2.8% — Earnings due 2026-11-05 — pre-report positioning.
Medium confidence
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -2.38 | Insider Own | 30.62% | Shs Outstand | 37.65M | Perf Week | 8.96% |
| Market Cap | 224.39M | Forward P/E | — | EPS next Y | -2.26 | Insider Trans | -0.54% | Shs Float | 31.67M | Perf Month | -6.29% |
| Enterprise Value | 149.87M | PEG | — | EPS next Q | -0.68 | Short Float | 10.84% | Perf Quarter | -45.72% | ||
| Income | -94.00M | P/S | 22.44 | EPS this Y | — | Short Ratio | 3.68 | Perf Half Y | -64.27% | ||
| Sales | 10.00M | P/B | 0.60 | EPS next Y | — | ROA | -23.80% | Short Interest | 3.43M | Perf YTD | -54.95% |
| Book/sh | 9.96 | P/C | 0.70 | EPS next 5Y | — | ROE | -28.99% | 52W High | 25.96 -77.04% | Perf Year | -21.27% |
| Cash/sh | 8.47 | P/FCF | — | EPS past 3/5Y | — | ROIC | -28.08% | 52W Low | 4.81 23.91% | Perf 3Y | — |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 99.39% | Volatility | 8.35% 7.12% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | 14.47 | EPS Y/Y TTM | — | Oper. Margin | -1026.28% | ATR (14) | 0.45 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 17.19 | Sales Y/Y TTM | 233.33% | Profit Margin | -912.25% | RSI (14) | 45.34 | Recom | 2.17 |
| Dividend Gr. 3/5Y | — | Current Ratio | 17.19 | EPS Q/Q | 3.33% | SMA20 | 5.87% | Beta | 1.81 | Target Price | 23.50 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | 0.00% | SMA50 | -17.81% | Rel Volume | 1.15 | Prev Close | 5.80 |
| Employees | 61 | LT Debt/Eq | 0.01 | Earnings | Nov 05 | SMA200 | -61.96% | Avg Volume | 747.31K | Price | 5.96 |
| IPO Date | Sep 26, 2024 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 4.50% 63.65% | Net Debt/EBITDA | — | Volume | 860,031 | Change | 2.76% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-11-26 | Initiated | UBS | Neutral | $8.00 |
| Jul-31-26 | Reiterated | Roth Capital | $36 → $25 | |
| Jul-31-26 | Reiterated | Jefferies | Buy | $21 |
| May-27-26 | Initiated | Roth Capital | Buy | $36 |
| May-13-26 | Initiated | BTIG | Buy | $40 |
| Mar-27-26 | Initiated | Needham | Buy | $50 |
| Feb-18-26 | Upgrade | Jefferies | Hold → Buy | $7.00 |
| Feb-04-26 | Reiterated | Morgan Stanley | Equal Weight | $12 → $23 |
| Dec-08-25 | Upgrade | Morgan Stanley | Underweight → Equal Weight | $12 |
| Oct-22-25 | Upgrade | Citigroup | Neutral → Buy |
Latest News· Times ET
Nov-02-26
Oct-29-26
Oct-22-26
Oct-22-2602:45AM
Oct-14-26
Oct-14-2608:00AM
Oct-12-26
Oct-12-2605:35AM
Sep-28-26
Sep-28-2603:23AM
Sep-25-26
Sep-16-26
Sep-16-2612:01PM
Sep-09-26
Sep-09-2602:17PM
Sep-08-26
Sep-08-2608:00AM
Sep-05-26
Sep-05-2608:53AM
Sep-02-26
Aug-13-26
Aug-13-2603:34AM
Aug-06-26
Company
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | |
|---|---|---|---|---|---|---|
| Total Revenue | 10 | 9 | 0 | 0 | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | — | |
| Gross Profit | 10 | 9 | 0 | 0 | — | |
| Selling, General and Administrative Excl. Other | 29 | 28 | 19 | 15 | — | |
| Research and Development | 88 | 74 | 59 | 34 | — | |
| Other Operating Expense | 0 | 0 | 0 | -1 | — | |
| Operating Income | -105 | -93 | -78 | -48 | — | |
| Interest Expense | 0 | 1 | 2 | 8 | — | |
| Unusual Expense | — | — | — | — | — | |
| Non-Operating Income (Expense) | 12 | 13 | 9 | -8 | — | |
| Net Income Before Taxes | -94 | -81 | -71 | -64 | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | |
| Consolidated Net Income | -94 | -81 | -71 | -64 | — | |
| Net Income From Continuing Operations | -94 | -81 | -71 | -64 | — | |
| Net Income | -94 | -81 | -71 | -64 | — | |
| EPS (Recurring) | -2.38 | -2.24 | -1.98 | -1.87 | — | |
| EPS (Basic, Before Extraordinaries) | -2.38 | -2.24 | -1.98 | -1.87 | — | |
| EPS (Diluted) | -2.38 | -2.24 | -1.98 | -1.87 | — | |
| EBITDA | -94 | -80 | -69 | -56 | — | |
| Other After Tax Adjustments | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | |
| Price To Sales Ratio | 26.82 | 52.92 | — | — | — | |
| Gross Margin | 100.00 | 100.00 | — | — | — | |
| Operating Margin | -1,050.00 | -1,033.33 | — | — | — | |
| Net Margin | -940.00 | -900.00 | — | — | — | |
| Shares Outstanding | 45 | 36 | 36 | 34 | — | |
| Market Capitalization | 268 | 476 | 208 | — | — | |
| Operating Lease Expense | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Barton Shane | Principal Accounting Officer | Jun 30 '26 | Option Exercise | 6.53 | 20,216 | 132,018 | 20,216 | Jul 01 |
| Barton Shane | Principal Accounting Officer | Jun 30 '26 | Sale | 25.19 | 20,216 | 509,176 | 0 | Jul 01 |
| Barton Shane | Principal Accounting Officer | Jun 29 '26 | Sale | 25.21 | 42,350 | 1,067,576 | 0 | Jul 01 |
| Barton Shane | Principal Accounting Officer | Jun 29 '26 | Option Exercise | 6.61 | 39,718 | 262,542 | 42,350 | Jul 01 |
| GOLDSTEIN DOV A MD | Chief Financial Officer | Apr 23 '26 | Option Exercise | 4.38 | 3,542 | 15,514 | 36,575 | Apr 24 |
| RUBIN PAUL D | Chief Medical Officer | Apr 01 '26 | Option Exercise | 5.05 | 8,820 | 44,572 | 8,820 | Apr 03 |
| RUBIN PAUL D | Chief Medical Officer | Apr 01 '26 | Sale | 17.81 | 8,820 | 157,084 | 0 | Apr 03 |
| RUBIN PAUL D | Chief Medical Officer | Mar 02 '26 | Option Exercise | 4.77 | 7,433 | 35,470 | 7,433 | Mar 03 |
| RUBIN PAUL D | Chief Medical Officer | Mar 02 '26 | Sale | 20.30 | 7,433 | 150,890 | 0 | Mar 03 |
| GOLDSTEIN DOV A MD | Chief Financial Officer | Mar 01 '26 | Option Exercise | 4.38 | 3,542 | 15,514 | 33,033 | Mar 03 |
| RUBIN PAUL D | Chief Medical Officer | Feb 02 '26 | Option Exercise | 4.77 | 7,433 | 35,470 | 7,433 | Feb 03 |
| RUBIN PAUL D | Chief Medical Officer | Feb 02 '26 | Sale | 18.75 | 7,433 | 139,369 | 0 | Feb 03 |
| GOLDSTEIN DOV A MD | Chief Financial Officer | Feb 01 '26 | Option Exercise | 4.38 | 3,541 | 15,510 | 29,491 | Feb 03 |
| GOLDSTEIN DOV A MD | Chief Financial Officer | Jan 16 '26 | Option Exercise | 4.38 | 3,542 | 15,514 | 25,950 | Jan 21 |
| GOLDSTEIN DOV A MD | Chief Financial Officer | Jan 13 '26 | Option Exercise | 8.39 | 27,000 | 226,530 | 49,408 | Jan 15 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.